Skip to main content

Table 1 Acylcarnitine concentrations of screened newborns

From: Dynamic simulations on the mitochondrial fatty acid Beta-oxidation network

Acylcarnitines [μmol/l]

C4

C6

C8

C10

C12

C14

C16

C18

Middle Europe

healthy controls (n = 590.216)

median

0.38

0.12

0.10

0.09

0.13

0.21

4.37

0.97

  

IQR

0.27

0.14

0.07

0.09

0.09

0.13

2.18

0.52

 

MCAD deficiency (n = 63)

median

0.40

1.31

5.14

0.59

0.11

0.19

3.47

0.80

  

IQR

0.23

1.27

8.78

0.64

0.10

0.12

1.59

0.46

 

VLCAD deficiency (n = 5)

median

0.28

0.11

0.12

0.15

0.47

0.85

3.15

1.38

  

IQR

0.11

0.07

0.08

0.13

0.19

0.45

1.04

1.44

South Australia

MCAD deficiency (n = 13)

median

0.32

0.97

7.23

1.10

0.25

0.32

3.49

2.69

  

IQR

0.07

0.95

7.27

0.39

0.09

0.13

1.80

1.18

 

VLCAD deficiency (n = 3)

median

0.40

0.16

0.15

0.34

1.19

2.41

4.99

3.11

  

IQR

0.27

0.08

0.10

0.21

0.42

2.71

3.22

5.43

  1. Summary of regional dissimilarities of acylcarnitines (with even-chain saturated fatty acid acyl group) concentrations (median and interquartile range (IQR)) of newborns screened in Middle Europe and South Australia [28, 29].